The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies
Status:
Not yet recruiting
Trial end date:
2024-08-30
Target enrollment:
Participant gender:
Summary
To the patient of terminal biliary malignancy tumor, how should the patient's treatment plan
choose ? To address this problem, this study intends to analyze systemic venous
gemcitabine-based chemotherapy regimen combined with immune checkpoint inhibitors in patients
with advanced BTC, to evaluate the long-term efficacy and toxicity of patients, and to search
for predictable biomarkers. In order to clarify the advantages and disadvantages of
intravenous chemotherapy combined with immunotherapy for patients with advanced biliary
malignancy, provide certain basis for clinical work, and then select the most suitable
treatment plan for patients according to the different characteristics of individual
patients.